0001104659-24-046970.txt : 20240415 0001104659-24-046970.hdr.sgml : 20240415 20240415071310 ACCESSION NUMBER: 0001104659-24-046970 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240415 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240415 DATE AS OF CHANGE: 20240415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TELA Bio, Inc. CENTRAL INDEX KEY: 0001561921 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 455320061 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39130 FILM NUMBER: 24843095 BUSINESS ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484-320-2930 MAIL ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 8-K 1 tm2411582d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 15, 2024

TELA Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39130

45-5320061

(State or other jurisdiction of

incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

1 Great Valley Parkway, Suite 24

Malvern, Pennsylvania

19355

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (484) 320-2930

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		TELA		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01

Other Events.

On April 15, 2024, TELA Bio, Inc. issued a press release announcing the U.S. commercial launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix. A copy of this press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:

Exhibit No.		Document
99.1		Press Release of TELA Bio, Inc., dated April 15, 2024.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELA BIO, INC.

	By:	/s/ Antony Koblish
	Name:	Antony Koblish
	Title:	President, Chief Executive Officer and Director

Date: April 15, 2024

EX-99.1 2 tm2411582d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

A black and red logo

Description automatically generated

TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures

Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.)

MALVERN, Pa., April 15, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, specifically designed for use in laparoscopic and robotic-assisted inguinal hernia repair.

OviTex IHR is available in three configurations, consisting of a three- or four-layer anatomically shaped device or a three-layer rectangular device, to provide surgeons with a variety of options to address unique patient, technique or procedure-related characteristics. Each configuration has been designed for trocar-compatibility to enhance use of these products in laparoscopic and robotic procedures.

OviTex IHR builds on the existing OviTex portfolio, a next generation reinforced biologic that utilizes layers of ovine (sheep) rumen interwoven with just enough polymer suture for added strength, designed to minimize permanent polymer footprint. OviTex has over 8 years of clinical experience with more than 45,000 implantations and 35 published or presented works demonstrating its clinical efficacy in hernia repair, based on sales and internal data.

This data includes a prior retrospective study, Minimizing Retained Foreign Body in Hernia Repair Using a Novel Technique: Reinforced Biologic Augmented Repair (ReBAR), examining OviTex Core Permanent in a variety of hernia repair techniques and indications. The study, led by Dr. Paul Szotek, Medical Director of the Indiana Hernia Center, included the analysis of 259 patients who underwent robotic inguinal hernia TAPP repair using the ReBAR technique and demonstrated a low 1.2% recurrence rate with an average follow up of 1.5 years.

“Since 2018, utilization of OviTex in inguinal hernia repairs has consistently delivered exceptional clinical value, evidenced by low recurrence rates and an unprecedented level of patient satisfaction,” said Dr. Szotek. “The introduction of OviTex IHR signifies a pivotal moment in the advancement of the OviTex technology.”

“OviTex IHR, designed specifically for inguinal hernia repair and robotic-compatibility usage, is the next logical addition to our growing OviTex portfolio,” said Antony Koblish, President and Chief Executive Officer of TELA Bio. “The inguinal hernia market has historically been dominated by permanent synthetic mesh with few viable alternatives to address the shortcomings of those materials. With the introduction of OviTex IHR, we are addressing this need and providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response.”

To learn more, visit ovitex.com

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.

About OviTex IHR Devices

OviTex IHR is intended for use as a surgical mesh to reinforce and/or repair tissue where weakness exists. Indications for use include the repair of inguinal hernias that require the use of reinforcing material to obtain the desired surgical outcome.

Do not use OviTex IHR in patients with a known sensitivity to materials of ovine (sheep) origin. Use of OviTex IHR in this patient population may result in an allergic or immunological reaction.

The following adverse events have been reported for surgical repair of hernias (with or without a surgical mesh): pain, infection, dysphagia, hernia recurrence, dehiscence, abscess, adhesion, bowel obstruction, bleeding, fistula, seroma, perforation, mesh migration, and mesh contraction.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA's management, including with respect to the launch of OviTex IHR Reinforced Tissue Matrix. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others the impact to our business from macroeconomic conditions, including the impact of pandemics or epidemics, recessionary concerns, banking instability, and inflationary pressures, potentially impacting our ability to market our products, demand for our products due to the deferral of elective procedures, the labor and staffing environment in the healthcare industry, disruption in our supply chain, or pricing pressures concerning our products or the procedures using our products; our ability to achieve or sustain profitability; our ability to gain market acceptance for our products and to accurately forecast and meet customer demand; our ability to compete successfully; that data from earlier studies related to our products and interim data from ongoing studies may not be replicated in later studies or indicative of future data; that data obtained from clinical studies using our product may not be indicative of outcomes in other surgical settings; our ability to enhance our product offerings; development and manufacturing problems; capacity constraints or delays in production of our products; maintenance of coverage and adequate reimbursement for procedures using our products; product defects or failures. These and other risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Investor Contact

Greg Chodaczek

347-620-7010

ir@telabio.com

Media Contact

Lisa Novy-Wikowski

484-354-6782

lnovywikowski@telabio.com

EX-101.SCH 3 tela-20240415.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tela-20240415_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tela-20240415_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2411582d1_ex99-1img001.jpg GRAPHIC begin 644 tm2411582d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 15, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 15, 2024
Entity File Number	001-39130
Entity Registrant Name	TELA Bio, Inc.
Entity Central Index Key	0001561921
Entity Tax Identification Number	45-5320061
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1 Great Valley Parkway
Entity Address, Address Line Two	Suite 24
Entity Address, City or Town	Malvern
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19355
City Area Code	484
Local Phone Number	320-2930
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	TELA
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://telabio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tela-20240415.xsd tela-20240415_lab.xml tela-20240415_pre.xml tm2411582d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2411582d1_8k.htm": { "nsprefix": "TELA", "nsuri": "http://telabio.com/20240415", "dts": { "schema": { "local": [ "tela-20240415.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "tela-20240415_lab.xml" ] }, "presentationLink": { "local": [ "tela-20240415_pre.xml" ] }, "inline": { "local": [ "tm2411582d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://telabio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2411582d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2411582d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://telabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-046970-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-046970-xbrl.zip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end XML 18 tm2411582d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001561921 2024-04-15 2024-04-15 iso4217:USD shares iso4217:USD shares false 0001561921 8-K 2024-04-15 TELA Bio, Inc. DE 001-39130 45-5320061 1 Great Valley Parkway Suite 24 Malvern PA 19355 484 320-2930 false false false false Common Stock, par value $0.001 per share TELA NASDAQ true true false